A phase II trial of murine monoclonal antibody 17-1A and interferon-γ: Clinical and immunological data

Mansoor N. Saleh; Albert F. LoBuglio; Richard H. Wheeler; Kimberly J. Rogers; Amy Haynes; Jeannette Y. Lee; M. B. Khazaeli

doi:10.1007/BF01771455

A phase II trial of murine monoclonal antibody 17-1A and interferon-γ: Clinical and immunological data

Mansoor N. Saleh, Albert F. LoBuglio, Richard H. Wheeler, Kimberly J. Rogers, Amy Haynes, Jeannette Y. Lee, M. B. Khazaeli

Research output: Contribution to journal › Article › peer-review

52 Citations (Scopus)

Abstract

A group of 15 patients with metastatic colorectal adenocarcinoma received a combination of interferon γ (0.1 mg/m², days 1-15) and the murine monoclonal antibody 17-1A (400 mg, days 5, 7, 9 and 12). The treatment was tolerated with minimal toxicity. Of the 14 evaluable patients, 13 developed human antibody to murine 17-1A, with 11 patients demonstrating antibody to the variable region of 17-1A (anti-idiotype). Antibody to the variable region was inhibited by 17-1A but not by mouse immunoglobulin. Sera from patients with substantial anti-idiotype reactivity were capable of inhibiting the binding of murine 17-1A to antigen expressing LS174-T cells thus indicating the presence of antibody directed against the 17-1A combining site (mirror-image anti-idiotype). The median survival of the whole group was 56 weeks and there was no correlation between clinical response/survival and the development of anti-idiotype antibody.

Original language	English
Pages (from-to)	185-190
Number of pages	6
Journal	Cancer Immunology, Immunotherapy
Volume	32
Issue number	3
DOIs	https://doi.org/10.1007/BF01771455
Publication status	Published - May 1990
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/BF01771455

Cite this

@article{9517aa882b3048b0af2642027d59f0f3,

title = "A phase II trial of murine monoclonal antibody 17-1A and interferon-γ: Clinical and immunological data",

abstract = "A group of 15 patients with metastatic colorectal adenocarcinoma received a combination of interferon γ (0.1 mg/m2, days 1-15) and the murine monoclonal antibody 17-1A (400 mg, days 5, 7, 9 and 12). The treatment was tolerated with minimal toxicity. Of the 14 evaluable patients, 13 developed human antibody to murine 17-1A, with 11 patients demonstrating antibody to the variable region of 17-1A (anti-idiotype). Antibody to the variable region was inhibited by 17-1A but not by mouse immunoglobulin. Sera from patients with substantial anti-idiotype reactivity were capable of inhibiting the binding of murine 17-1A to antigen expressing LS174-T cells thus indicating the presence of antibody directed against the 17-1A combining site (mirror-image anti-idiotype). The median survival of the whole group was 56 weeks and there was no correlation between clinical response/survival and the development of anti-idiotype antibody.",

author = "Saleh, {Mansoor N.} and LoBuglio, {Albert F.} and Wheeler, {Richard H.} and Rogers, {Kimberly J.} and Amy Haynes and Lee, {Jeannette Y.} and Khazaeli, {M. B.}",

year = "1990",

month = may,

doi = "10.1007/BF01771455",

language = "English",

volume = "32",

pages = "185--190",

journal = "Cancer Immunology, Immunotherapy",

issn = "0340-7004",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "3",

}

TY - JOUR

T1 - A phase II trial of murine monoclonal antibody 17-1A and interferon-γ

T2 - Clinical and immunological data

AU - Saleh, Mansoor N.

AU - LoBuglio, Albert F.

AU - Wheeler, Richard H.

AU - Rogers, Kimberly J.

AU - Haynes, Amy

AU - Lee, Jeannette Y.

AU - Khazaeli, M. B.

PY - 1990/5

Y1 - 1990/5

N2 - A group of 15 patients with metastatic colorectal adenocarcinoma received a combination of interferon γ (0.1 mg/m2, days 1-15) and the murine monoclonal antibody 17-1A (400 mg, days 5, 7, 9 and 12). The treatment was tolerated with minimal toxicity. Of the 14 evaluable patients, 13 developed human antibody to murine 17-1A, with 11 patients demonstrating antibody to the variable region of 17-1A (anti-idiotype). Antibody to the variable region was inhibited by 17-1A but not by mouse immunoglobulin. Sera from patients with substantial anti-idiotype reactivity were capable of inhibiting the binding of murine 17-1A to antigen expressing LS174-T cells thus indicating the presence of antibody directed against the 17-1A combining site (mirror-image anti-idiotype). The median survival of the whole group was 56 weeks and there was no correlation between clinical response/survival and the development of anti-idiotype antibody.

AB - A group of 15 patients with metastatic colorectal adenocarcinoma received a combination of interferon γ (0.1 mg/m2, days 1-15) and the murine monoclonal antibody 17-1A (400 mg, days 5, 7, 9 and 12). The treatment was tolerated with minimal toxicity. Of the 14 evaluable patients, 13 developed human antibody to murine 17-1A, with 11 patients demonstrating antibody to the variable region of 17-1A (anti-idiotype). Antibody to the variable region was inhibited by 17-1A but not by mouse immunoglobulin. Sera from patients with substantial anti-idiotype reactivity were capable of inhibiting the binding of murine 17-1A to antigen expressing LS174-T cells thus indicating the presence of antibody directed against the 17-1A combining site (mirror-image anti-idiotype). The median survival of the whole group was 56 weeks and there was no correlation between clinical response/survival and the development of anti-idiotype antibody.

UR - http://www.scopus.com/inward/record.url?scp=0025667265&partnerID=8YFLogxK

U2 - 10.1007/BF01771455

DO - 10.1007/BF01771455

M3 - Article

C2 - 2126988

AN - SCOPUS:0025667265

SN - 0340-7004

VL - 32

SP - 185

EP - 190

JO - Cancer Immunology, Immunotherapy

JF - Cancer Immunology, Immunotherapy

IS - 3

ER -

A phase II trial of murine monoclonal antibody 17-1A and interferon-γ: Clinical and immunological data

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this